Cardio Diagnostics
Get Started
Hero Background

HeartRisk™

Real-Time Population Insights Platform

Coronary Heart Disease and Heart Attacks

Helping Organizations Understand, Benchmark and Address Cardiovascular Risk Across Their Population

HeartRisk™ is a population cardiovascular risk intelligence platform that integrates HIPAA-compliant anonymized clinical, industry, claims, and geographic data to offer a comprehensive view of heart attack risk and coronary heart disease across their population.

It enables employers and union leadership to:

  • Quantify heart attack risk and coronary heart disease in real-time
  • Project future cost implications
  • Tailor benefits offering to mitigate cardiovascular risk and reduce healthcare spend
  • Track population risk profile over time
  • Benchmark prevalence against regional and industry data

Who HeartRisk™ Serves

Employers

Identify cardiovascular risk trends across your workforce, understand projected healthcare costs, and implement proactive wellness and care management strategies to reduce claims and improve employee well-being.

Employers

Employers

Consultants

Consultants

Consultants

Use insights to better advise your employer clients on risk mitigation strategies, plan design, and vendor selection, backed by population-level data and projections.

Healthcare Systems & Provider Groups

Healthcare Systems & Provider Groups

Healthcare Systems & Provider Groups

Understand the cardiovascular disease burden in your population, improve risk-based contracting, and design targeted care programs aligned with value-based care goals.

Request a Demo

HeartRisk™ Platform Insights

See how many employees or members are engaging with testing and follow-up support, helping you measure program adoption and reach.
When employees or members undergo testing with our Epi+Gen CHD test, data will be aggregated in a compliant manner to provide insights into heart attack risk prevalence in your population, so preventive action can be taken before a costly event occurs.
When employees or members undergo testing with our PrecisionCHD test, data will be aggregated in a compliant manner to provide insights into coronary heart disease prevalence and disease drivers in your population, so preventive action can be taken to reduce healthcare spend.
Understand the potential financial impact of coronary heart disease and heart attacks to your organization to inform risk mitigation strategies and reduce spend.
Compare your population's prevalence data against national, regional, and/or industry-specific benchmarks to identify strengths and potential areas for improvement.
Track year-over-year trends of coronary heart disease, heart attack risk and cost impact in your population.
Visual content

Leverage HeartRisk™ to Lower Risk, Reduce Healthcare Spend, and Drive ROI for Your Organization

Contact Us

Who We Serve

PatientsProvidersEmployers

Our Solutions

OverviewEpi+Gen CHD™PrecisionCHD™HeartRisk™CardioInnovate360™

Company

About UsAbout CVDCareersTechnologyResourcesContact Us

Investors

Stock InformationSEC FilingsPress ReleasesPresentationsEmail SubscriptionCorporate GovernanceContact Investor Relations
Contact Us

2026 Cardio Diagnostics, Inc.

Privacy PolicyTerms of UseHIPAA Notice

The Cardio Diagnostics clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical laboratory testing. The Epi+Gen CHD™ and PrecisionCHD™ tests were developed, and their performance characteristics were determined by Cardio Diagnostics. These tests should be ordered by a licensed healthcare provider, and test results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms, and other relevant clinical information. These tests are intended for clinical purposes and have not been cleared or approved by the U.S. Food and Drug Administration (FDA).

For the Epi+Gen CHD™ test, a lower risk result does not eliminate the possibility of a coronary heart disease event occurring or that coronary heart disease is present, and a higher risk result does not imply a diagnosis of coronary heart disease or that a coronary heart disease event will occur. For the PrecisionCHD™ test, a "Signal Detected" result is not a diagnosis of coronary heart disease, and a "Signal Not Detected" result does not eliminate the possibility that coronary heart disease is present or could occur in the future. False positive and false negative test results do occur. Rx only.

In addition to a federal CLIA license, the Cardio Diagnostics clinical laboratory holds active state clinical laboratory licenses in California, Maryland, Pennsylvania, and Rhode Island. The laboratory is not currently licensed to process patient samples originating from the state of New York.